Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukocyte-endothelial cell interaction refers to the dynamic, multi-step process by which leukocytes (white blood cells) adhere to and migrate across the vascular endothelium. This process is fundamental for immune surveillance, inflammation, and tissue repair. It enables leukocytes to exit the bloodstream at sites of infection or injury and enter tissues where they perform their immune functions. The interaction occurs in several coordinated steps: Tethering, Rolling, Activation, Firm Adhesion, and Transmigration. Key molecules involved include selectins (E-, P-, L-selectin), integrins (e.g., β2-integrins like LFA-1/CD11a/CD18), and immunoglobulin superfamily molecules such as ICAM-1 and VCAM-1. Dysregulation or excessive activation can contribute to chronic inflammatory diseases such as inflammatory bowel disease, ischemia/reperfusion injury, and autoimmune disorders. Therapeutic strategies targeting these interactions aim either to block inappropriate recruitment (anti-inflammatory) or enhance it when needed for host defense or tissue repair.
Blocking leukocyte recruitment; Enhancing leukocyte recruitment
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukocyte-Endothelial Cell Interaction.